secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-08-10T20:05:19+00:00
Accession:  0001193125-26-342335
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q2 2026 net loss $109.5M; TRUTAKNA approved and launched
--------------------------------------------------------------------------

- Q2 2026 net loss $109.5M ($1.52/share) vs $76.5M ($1.20) in Q2 2025; cash $499.2M at June 30, 2026.
- FDA granted accelerated approval for TRUTAKNA in IgAN; first BAFF/APRIL inhibitor; U.S. launch underway.
- ORIGIN 3 final efficacy analysis expected Q3 2026; sBLA submission to FDA expected Q4 2026.
- Nancy Boman named Chief Regulatory Officer, succeeding William Turner upon his retirement in Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/0001193125-26-342335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer